Abstracts Archive - Page 2391 of 2425 - ACR Meeting Abstracts

Abstract Number: 459 • 2012 ACR/ARHP Annual Meeting
Long-Term Safety of Rituximab: 10-Year Follow-up in the Rheumatoid Arthritis Global Clinical Trial Program
Ronald F. van Vollenhoven¹, Paul Emery², Clifton O. Bingham III³, Edward Keystone⁴, Roy Fleischmann⁵, Daniel Furst⁶, Nicola Tyson⁷, Abdul Mehbob⁸ and Patrica B. Lehane⁷, ¹Karolinska University Hospital, Stockholm, Sweden, ²Division of Rheumatic & Musculoskeletal Disease, University of Leeds, Leeds, United Kingdom, ³Department of Medicine, Johns Hopkins University, Baltimore, MD, ⁴The Rebecca MacDonald Centre for Arthritis and Autoimmunity, Mount Sinai Hospital, Toronto, ON, Canada, ⁵Rheumatology, University of Texas Southwestern Medical Center and Metroplex Clinical Research Center, Dallas, TX, ⁶Div of Rheumatology, UCLA Medical School, Los Angeles, CA, ⁷Roche Products Limited, Welwyn Garden City, United Kingdom, ⁸Roche Products Ltd., Welwyn Garden City, United Kingdom
Background/Purpose: This analysis evaluated the long-term safety of rituximab (RTX) in RA patients (pts) in a global clinical trial program. Methods: Pooled observed case analysis…
Abstract Number: 460 • 2012 ACR/ARHP Annual Meeting
Real-World Efficacy and Safety of Abatacept Treatment for Rheumatoid Arthritis: 12-Month Interim Analysis of the Action Study
H. Nüßlein¹, R. Alten², M. Galeazzi³, H. M. Lorenz⁴, Dimitrios Boumpas⁵, M. T. Nurmohamed⁶, W. Bensen⁷, Gerd Burmester⁸, H.-H. Peter⁹, F. Rainer¹⁰, Karel Pavelka¹¹, M. Chartier¹², C. Poncet¹³, C. Rauch¹⁴ and M. Le Bars¹⁵, ¹University Erlangen, Nürnberg, Germany, ²Schlosspark-Klinik, University Medicine, Berlin, Germany, ³University of Siena, Siena, Italy, ⁴University Hospital Heidelberg, Heidelberg, Germany, ⁵Panepistimio Kritis, Rethymnon, Greece, ⁶VU University Medical Center/Jan van Bremen Research Institute, Amsterdam, Netherlands, ⁷St. Joseph's Hospital and McMaster University, Hamilton, ON, Canada, ⁸Charité-Universitätsmedizin, Berlin, Germany, ⁹University Medical Center Freiburg, Freiburg, Germany, ¹⁰Hospital Barmherzige Brueder, Graz, Austria, ¹¹Institute of Rheumatology, Prague, Czech Republic, ¹²Chiltern International, Neuilly, France, ¹³Docs International, Sévres, France, ¹⁴Bristol-Myers Squibb, Munich, Germany, ¹⁵Bristol-Myers Squibb, Rueil Malmaison, France
Background/Purpose: Randomized controlled trials (RCTs) of abatacept (ABA) in patients (pts) with RA have demonstrated sustained, long-term efficacy, high pt retention, and consistent safety.1 Data…
Abstract Number: 461 • 2012 ACR/ARHP Annual Meeting
Patterns of Tocilizumab Use, and Dosing Among Patients with Rheumatoid Arthritis in the Clinical Practice. Preliminary Analyses of ACT-Life Study
J.V. Tovar Beltrán¹, M.A. Guzmán Úbeda², I. Mateo Bernardo³, Rosario García-Vicuña⁴, M. Rodríguez-Gómez⁵, M. Belmonte-Serrano⁶, C. Marras⁷, E. Loza Cortina⁸, E. Pérez Pampin⁹, V. Vila Fayos¹⁰, A.B. Romero Silva¹¹ and A. Balsa¹², ¹Hospital General Universitario de Elche, Alicante, Spain, ²Hospital Universitario Virgen de las Nieves, Granada, Spain, ³Hospital Universitario 12 de Octubre, Madrid, Spain, ⁴Hospital Universitario La Princesa, Madrid, Spain, ⁵Complejo Hospitalario Universitario de Ourense, Ourense, Spain, ⁶Hospital General de Castellón, Castellón, Spain, ⁷Hospital Universitario Virgen de la Arrixaca, Murcia, Spain, ⁸Hospital de Navarra, Navarra, Spain, ⁹Complejo Hospitalario Universitario de Santiago, Santiago de Compostela, Spain, ¹⁰Hospital Comarcal de Vinaroz, Castellón, Spain, ¹¹Roche Farma, Madrid, Spain, ¹²Rheumatology, Hospital La Paz, Madrid, Spain
Background/Purpose: Currently, the available evidence about tocilizumab (TCZ) use for the treatment of rheumatoid arthritis (RA) in daily clinical practice is scarce. This study was…
Abstract Number: 462 • 2012 ACR/ARHP Annual Meeting
Subcutaneous Abatacept: Long-Term Data From the Acquire Trial
M. C. Genovese¹, C. Pacheco-Tena², A. Covarrubias³, Gustavo Leon⁴, E. Mysler⁵, M. Keiserman⁶, R. Valente⁷, P. Nash⁸, J. A. Simon-Campos⁹, J. Box¹⁰, C. Legerton III¹¹, E. Nasonov¹², P. Durez¹³, I. Delaet¹⁴ and R. Alten¹⁵, ¹Stanford University, Palo Alto, CA, ²Universidad Autónoma de Chihuahua, Chihuahua, Mexico, ³Centro Medico De Las Americas, Merida, Mexico, ⁴Instituto De Ginecologia Y Reproduccion, Lima, Peru, ⁵Organización Médica de Investigación, Buenos Aires, Argentina, ⁶Pontificial Catholic University School of Medicine, Porto Alegre, Brazil, ⁷Arthritis Center of Nebraska, Lincoln, NE, ⁸Rheumatology Research Unit, Nambour Hospital, Sunshine Coast and Department of Medicine, University of Queensland, Queensland, Australia, ⁹Centro De Especialidades Médicas/Universidad Marista, Merida, Mexico, ¹⁰Carolina Bone and Joint, Charlotte, NC, ¹¹Low Country Rheumatology, Charleston, SC, ¹²Institute of Rheumatology, Moscow, Russia, ¹³Université Catholique de Louvain, Brussels, Belgium, ¹⁴Bristol-Myers Squibb, Princeton, NJ, ¹⁵Schlosspark-Klinik, University Medicine, Berlin, Germany
Background/Purpose: The Abatacept (ABA) Comparison of Sub[QU]cutaneous (SC) versus Intravenous (IV) in Inadequate Responders to MethotrexatE (MTX) (ACQUIRE) study showed comparable efficacy and safety of…
Abstract Number: 463 • 2012 ACR/ARHP Annual Meeting
Drug Survival, Efficacy and Predictors for Survival On Tocilizumab in Real-Life Patients with Rheumatoid Arthritis; Results From the Swedish Biologics Register
Helena Forsblad-d'Elia¹, Karin Bengtsson¹, Lars-Erik Kristensen² and Lennart TH Jacobsson¹, ¹Department of Rheumatology and Inflammation Research, Sahlgrenska Academy at University of Gothenburg, Gothenburg, Sweden, ²Dept of Clinical Sciences, Lund, Section for Rheumatology, Lund University, Faculty of Medicine, Malmö, Sweden
Background/Purpose: To evaluate drug survival, clinical response and predictors for drug survival for tocilizumab in patients with rheumatoid arthritis (RA) with inadequate response and/or adverse…
Abstract Number: 464 • 2012 ACR/ARHP Annual Meeting
Rituximab for Treatment of Rheumatoid Arthritis: Treatment Effectiveness in the Corrona Database
Leslie R. Harrold¹, George W. Reed¹, Robert P. Magner¹, Katherine C. Saunders², Jeffrey D. Greenberg³, Joel M. Kremer⁴, Ani John⁵, William Reiss⁵, Steve Zlotnick⁶ and Ashwini Shewade⁵, ¹University of Massachusetts Medical School, Worcester, MA, ²Corrona, LLC., Southborough, MA, ³New York Hospital for Joint Disease, New York, NY, ⁴Center for Rheumatology, Albany Medical College, Albany, NY, ⁵Genentech Inc., South San Francisco, CA, ⁶Genentech, Inc., a Member of the Roche Group, South San Francisco, CA
Background/Purpose: Rituximab (RTX) in combination with methotrexate is used for the treatment of adult RA with an inadequate response to TNF antagonists. We aimed to…
Abstract Number: 465 • 2012 ACR/ARHP Annual Meeting
The Comparative Effectiveness of Oral Methotrexate Versus Subcutaneous Methotrexate for the Treatment of Early Rheumatoid Arthritis
Glen S. Hazlewood¹, J. Carter Thorne², Janet E. Pope³, Gilles Boire⁴, Boulos Haraoui⁵, Carol A. Hitchon⁶, Edward Keystone⁷, Diane Tin⁸, CATCH Investigators⁹ and Vivian P. Bykerk¹⁰, ¹Medicine, University of Toronto, Toronto, ON, Canada, ²Southlake Regional Health Centre, Newmarket, ON, Canada, ³Medicine, Divsion of Rheumatology, Schulich School of Medicine and Dentistry, Western University, London, ON, Canada, ⁴Rheumatology Division, Centre Hospitalier Universitaire de Sherbrooke, Université de Sherbrooke, Sherbrooke, QC, Canada, ⁵Osteoarthritis Research Unit, University of Montreal Hospital Research Centre (CRCHUM), Montreal, QC, Canada, ⁶University of Manitoba, Winnipeg, MB, Canada, ⁷University of Toronto, Toronto, ON, Canada, ⁸The Arthritis Program, Southlake Regional Health Centre, Newmarket, ON, Canada, ⁹Toronto, ON, Canada, ¹⁰Rheumatology, Hospital for Special Surgery, New York, NY
Background/Purpose: To determine the comparative effectiveness of subcutaneous (sc) versus oral methotrexate (MTX) as initial therapy for patients with early rheumatoid arthritis (ERA) in routine…
Abstract Number: 466 • 2012 ACR/ARHP Annual Meeting
Synovialitis Plus Articular Cartilage Monitoring Via Magnetic Resonance Imaging and Ultrasound Under Tocilizumab Therapy in Patients with Rheumatoid Arthritis
Maria Hoehle¹ and Michael Finkenstaedt², ¹Rheumatology, Hamburg, Germany, ²Private Practice for Radiology and Neuroradiology, Hamburg, Germany
Background/Purpose: To determine remission in RA, recent publications point out the importance of radiological parameters, besides scores like DAS28, TJC, SJC, CrP, patient global assessment,…
Abstract Number: 467 • 2012 ACR/ARHP Annual Meeting
Seropositive Rheumatoid Arthritis Patients with an Inadequate Response to Tumor Necrosis Factor Inhibitors Achieve Improved Clinical Effectiveness After Switching to Rituximab Versus Switching to an Alternative Tumor Necrosis Factor Inhibitor
Andrea Rubbert-Roth¹, Axel Finckh², Piercarlo Sarzi-Puttini³, Jacques-Eric Gottenberg⁴, Denis Choquette⁵, Victor Martínez Taboada⁶, Leonor Barile-Fabris⁷, Carol Chung⁸, Lykke Hinsch-Gylvin⁹ and Paul Emery¹⁰, ¹Internal Medicine I, University of Cologne, Cologne, Germany, ²Department of Medical Specialities, University of Geneva, Geneva, Switzerland, ³Rheumatology Unit, L Sacco University Hospital, Milan, Italy, ⁴Strasbourg University Hospital, Strasbourg, France, ⁵Rheumatology, Institut de rhumatologie de Montréal (IRM), Montréal, QC, Canada, ⁶Rheumatology Department, Hospital Universitario Marqués de Valdecilla, Santander, Spain, ⁷Instituto Mexicano del Seguro Social, Hospital de Especialidades Centro Médico Nacional Siglo XXI, Mexico City, Mexico, ⁸Genentech Inc., South San Francisco, CA, ⁹F Hoffmann-La Roche Ltd, Basel, Switzerland, ¹⁰Division of Rheumatic & Musculoskeletal Disease, University of Leeds, Leeds, United Kingdom
Background/Purpose: RA patients (pts) with an inadequate response (IR) to a tumor necrosis factor inhibitor (TNFi) may achieve greater benefit by switching to rituximab (RTX)…
Abstract Number: 468 • 2012 ACR/ARHP Annual Meeting
Adalimumab Treatment Is Associated with Decreased Concomitant Rheumatoid Arthritis Medication Use Over 24 Months
Daniel Furst¹, Neelufar Mozaffarian², Shannon Grant³, Mary Cifaldi², Jerry Clewell², Joel M. Kremer⁴ and James Shaw⁵, ¹Div of Rheumatology, UCLA Medical School, Los Angeles, CA, ²Abbott Laboratories, Abbott Park, IL, ³Axio Research LLC, Seattle, WA, ⁴Albany Medical College and The Center for Rheumatology, Albany, NY, ⁵Global Health Economics and Outcomes Research, Abbott Laboratories, Abbott Park, IL
Background/Purpose: Adalimumab (ADA) is an effective medication in the treatment of rheumatoid arthritis (RA). However, it is not clear whether the use of ADA is associated…
Abstract Number: 469 • 2012 ACR/ARHP Annual Meeting
Intra Articular Injections in Patients with Rheumatoid Arthritis: Analyses From the Behandelstrategiën Study
E. Gvozdenovic¹, L. Dirven¹, M. van den Broek², Kh Han³, T.H.E. Molenaar⁴, R. Landewe⁵, W.F. Lems⁶ and C.F. Allaart¹, ¹Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ²Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ³Rheumatology, Maasstad hospital, Rotterdam, Netherlands, ⁴Dept of Rheumatology, Groene Hart Hospital, Gouda, Netherlands, ⁵Division of Clinical Immunology and Rheumatology, Academic Medical Center / University of Amsterdam, Amsterdam, Netherlands, ⁶Rheumatology, VU University medical center, Amsterdam, Netherlands
Background/Purpose: Intra articular (IA) corticosteroid injections aim at amelioration of symptoms of local inflammation in rheumatoid arthritis (RA). Some patients also report a systemic effect.…
Abstract Number: 430 • 2012 ACR/ARHP Annual Meeting
Comprehensive Microrna Analysis Identifies Mir-24, Mir-26a, and Mir-125a-5p As Plasma Biomarkers for Rheumatoid Arthritis
Koichi Murata¹, Moritoshi Furu², Hiroyuki Yoshitomi³, Masahiro Ishikawa¹, Hideyuki Shibuya¹, Hiromu Ito² and Shuichi Matsuda¹, ¹Department of Orthopaedic Surgery, Kyoto University Graduate School of Medicine, Kyoto, Japan, ²Department of the Control for Rheumatic Diseases, Graduate School of Medicine, Kyoto University, Kyoto, Japan, ³Department of Innovation Center for Immunoregulation Technologies and Drugs, Kyoto University Graduate School of Medicine, Kyoto, Japan
Background/Purpose: MicroRNAs (miRNAs) are present in human plasma in a stable form despite the endogenous RNase activity. Plasma miRNAs are non-invasive biomarker for cancer detection…
Abstract Number: 431 • 2012 ACR/ARHP Annual Meeting
Basic and Clinical Significance of Interleukin 6 (IL-6) in AA Amyloidosis with RA
Kazuyuki Yoshizaki, Prabha Tiwari, Lokesh P. Tripathi, Shandar Ahmad, Kenji Mizuguchi, Teppei Nishikawa-Matsumura, Tomoyasu Isobe and Soken-Nakazawa J. Song, Osaka University, Osaka, Japan
Background/Purpose: Cytokine-induced hepatic serum amyloid A (SAA) is associated with the pathogenesis of AA amylodosis, a fatal disease with deposition of AA amyloid fibril on…
Abstract Number: 432 • 2012 ACR/ARHP Annual Meeting
Identification and Characterization of Fibrinogen-Specific T Cells in Patients with Rheumatoid Arthritis
Laura Su¹ and Mark M. Davis², ¹The Division of Immunology and Rheumatology, Stanford University School of Medicine, Stanford, CA, ²Department of Microbiology and Immunlogy and Howard Hughes Medical Institute, Stanford University School of Medicine, Stanford, CA
Background/Purpose: Rheumatoid arthritis (RA) is a common, highly debilitating systemic inflammatory condition. To date, little is known about which autoantigens are involved in RA and…
Abstract Number: 433 • 2012 ACR/ARHP Annual Meeting
Genome Wide Association Analysis of Pain Reduction in Rheumatoid Arthritis Patients Treated with Anti-TNF Medication. Results of the DREAM and Danbio Registries
Marieke J.H. Coenen¹, Masha Umicevic-Mirkov², Hans Scheffer², Sophine B. Krintel³, Sita H. Vermeulen⁴, Julia S. Johansen³, Wietske Kievit⁵, Mart A.F.J. van de Laar⁶, Piet L.C.M. van Riel⁵, Barbara Franke² and Merete L. Hetland⁷, ¹Human Genetics (855), Department of Human Genetics, Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands, ²Human Genetics (855), Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands, ³DANBIO and Department of Rheumatology, Copenhagen University Hospital at Glostrup, Glostrup, Denmark, ⁴Human Genetics and Epidemiology, Biostatistics and HTA, Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands, ⁵Department of Rheumatology and DREAM registry, Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands, ⁶Department of Rheumatology and DREAM registry, Medisch Spectrum Twente & Twente University, Enschede, Netherlands, ⁷Copenhagen University Hospital Glostrup, Copenhagen, Denmark
Background/Purpose: Patients with rheumatoid arthritis (RA) rate pain relief as the highest priority in treatment outcome, and tumor necrosis factor inhibitors (anti-TNF) have proven very…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].